Cargando…

Healthcare resource utilization in a phase 3 trial of SER-109 in patients with recurrent Clostridioides difficile infection

Background: The estimated economic cost of Clostridioides difficile infection (CDI) is $5.4 billion annually, primarily attributed to acute-care costs. We previously reported data from ECOSPOR III that SER-109, an investigational oral microbiome therapeutic, was superior to placebo in reducing recur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cohen, Stuart, Louie, Thomas, Berenson, Charles, Amin, Alpesh, Lombardi, David, Pham, Sissi, Huang, Shirley, Wang, Elaine, Hasson, Brooke, McGovern, Barbara, Von Moltke, Lisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2022
Materias:	C. Difficile
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614905/ http://dx.doi.org/10.1017/ash.2022.196

Ejemplares similares

Integrated efficacy analysis from phase 3 studies of investigational microbiome therapeutic, SER-109, in recurrent Clostridioides difficile infection
por: Sims, Matthew, et al.
Publicado: (2023)

Efficacy and Safety of Investigational Microbiome Drug SER-109 for Treatment of Recurrent Clostridioides difficile Infection
por: McGovern, Barbara, et al.
Publicado: (2021)

Integrated safety analysis of phase 3 studies for investigational microbiome therapeutic, SER-109, in recurrent CDI
por: Sims, Matthew, et al.
Publicado: (2023)

Clostridioides difficile: A diagnostic intervention
por: Alsoubani, Majd, et al.
Publicado: (2022)

Clostridioides difficile Is Not Difficult to Predict in Hospital Settings
por: Alexander, Kinta, et al.
Publicado: (2021)

Utilizing vancomycin as secondary prophylaxis for the prevention of recurrent Clostridioides difficile infection
por: Kristen, Zeitler, et al.
Publicado: (2023)

Clinical Characteristics and Fecal Microbiome in Recurrent Versus Nonrecurrent Clostridioides difficile Infection
por: Lanjewar, Swapnil, et al.
Publicado: (2021)

Comparison of fidaxomicin to oral vancomycin for the treatment of Clostridioides difficile infection in hospitalized patients
por: Rao, A. Krishna, et al.
Publicado: (2022)

Evaluation of the genomic epidemiology and transmission of Clostridioides difficile infection across a community
por: Tesini, Brenda, et al.
Publicado: (2022)

Role of diagnostic stewardship in reducing healthcare facility-onset Clostridioides difficile infections
por: Shallal, Anita, et al.
Publicado: (2022)

Examining the impact of the COVID-19 pandemic on hospital-associated Clostridioides difficile infection
por: Ray, Michael, et al.
Publicado: (2023)

Did Clostridioides difficile Testing and Infection Rates Change During the COVID-19 Pandemic?
por: Hawes, Armani, et al.
Publicado: (2021)

Clostridioides difficile infection (CDI) treatment outcomes and recurrence factor at a pediatric hospital
por: Tran, Martin Tuan, et al.
Publicado: (2022)

Prospective audit and feedback of Clostridioides difficile PCR at the time of ordering increases appropriateness of testing
por: Tassone, Daniel, et al.
Publicado: (2022)

Characteristics of antibiotic exposures for surgical procedures prior to Clostridioides difficile diagnosis—Minnesota, 2018
por: D’Heilly, Paige, et al.
Publicado: (2022)

Impact of Two-Step Testing Algorithm on Reducing Hospital-Onset Clostridioides difficile Infections
por: Navalkele, Bhagyashri, et al.
Publicado: (2021)

Impact of early identification of patients meeting testing criteria for Clostridioides difficile on standard infection ratios
por: Krier, Brad, et al.
Publicado: (2023)

Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109: Secondary Analysis of a Randomized Clinical Trial
por: Garey, Kevin W., et al.
Publicado: (2023)

Effects of a hard stop for C. difficile testing: Provider uptake and patient outcomes
por: Doughman, Danielle, et al.
Publicado: (2023)

In veteran outpatients, antibiotics remain significant risk factor for community-acquired Clostridiodes difficile infection
por: Akpoji, Ukwen, et al.
Publicado: (2022)

Impact of exposure to potentially contaminated hospital beds on risk of hospital-onset C. difficile infection
por: Witt, Lucy, et al.
Publicado: (2022)

Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial
por: Sims, Matthew D., et al.
Publicado: (2023)

655. Analysis of Microbiome Diversity and Secondary Bile Acid Synthesis Following SER-109 or Placebo in Patients with First Recurrent or Multiply Recurrent Clostridioides difficile Infection
por: Kelly, Colleen R, et al.
Publicado: (2023)

SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI)
por: Khanna, Sahil, et al.
Publicado: (2022)

19. The Impact of Investigational Purified Microbiome Therapeutic SER-109 on Health-Related Quality of Life (HRQoL) of Patients with Recurrent Clostridioides difficile Infection (rCDI) in ECOSPOR III, a Placebo-Controlled Clinical Trial
por: Hohmann, Elizabeth, et al.
Publicado: (2021)

Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile
por: Huhulescu, Steliana, et al.
Publicado: (2011)

Did Clostridioides difficile testing and infection rates change during the COVID-19 pandemic?
por: Hawes, Armani Minasian, et al.
Publicado: (2021)

Infection of hamsters with the UK Clostridium difficile ribotype 027 outbreak strain R20291
por: Buckley, Anthony M., et al.
Publicado: (2011)

A cortex-specific penicillin-binding protein contributes to heat resistance in Clostridioides difficile spores
por: Alabdali, Yasir Adil Jabbar, et al.
Publicado: (2021)

653. Rapid Change in Microbiome Profiles Regardless of Diagnostic Method in a Post Hoc Comparative Analysis of Phase 3 Trials of Fecal Microbiota Spores, Live-brpk (formerly SER-109) for the Prevention of Recurrent Clostridioides difficile Infection (rCDI)
por: Gonzales-Luna, Anne J, et al.
Publicado: (2023)

Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota–Based Therapeutic
por: Berenson, Charles S, et al.
Publicado: (2023)

A systematic review of real-world healthcare resource use and costs of Clostridioides difficile infections
por: Malone, Daniel C., et al.
Publicado: (2023)

Patient Experiences with Clostridioides difficile Infection and Its Treatment: A Systematic Literature Review
por: Armstrong, Edward P., et al.
Publicado: (2023)

Clostridioides difficile infection: curbing a difficult menace
por: Khanna, Sahil, et al.
Publicado: (2022)

Immune response against Clostridioides difficile and translation to therapy
por: Sehgal, Kanika, et al.
Publicado: (2021)

Epidemiology of community-acquired and recurrent Clostridioides difficile infection
por: Fu, Yichun, et al.
Publicado: (2021)

The interplay of Clostridioides difficile infection and inflammatory bowel disease
por: Sehgal, Kanika, et al.
Publicado: (2021)

Transitions of care in Clostridioides difficile infection: a need of the hour
por: Khanna, Sahil, et al.
Publicado: (2022)

The contribution of bile acid metabolism to the pathogenesis of Clostridioides difficile infection
por: Mullish, Benjamin H., et al.
Publicado: (2021)

Fecal microbiota transplantation for recurrent Clostridioides difficile, safety, and pitfalls
por: Sandhu, Avnish, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f181ooqifptlb8k5vod3m4fkbt